Ulcérations buccales aphtoïdes inaugurales d’une maladie inflammatoire chronique de l’intestin induite par le sécukinumab
-
Published:2018-11
Issue:11
Volume:145
Page:676-682
-
ISSN:0151-9638
-
Container-title:Annales de Dermatologie et de Vénéréologie
-
language:fr
-
Short-container-title:Annales de Dermatologie et de Vénéréologie
Author:
Grimaux X.ORCID,
Leducq S.ORCID,
Goupille P.,
Aubourg A.,
Miquelestorena-Standley E.,
Samimi M.
Reference21 articles.
1. Biologic response modifiers: indications, implications, and insights;Davis;J Allergy Clin Immunol,2017
2. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases;Toussirot;Inflamm Allergy Drug Targets,2012
3. Mo2083, a randomized, double-blind, placebo-controlled study to evaluate the safety. Tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease;Targan;Gastroenterology,2012
4. Sécukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial;Hueber;Gut,2012
5. Sécukinumab failure in Crohn's disease: the yeast connection?;Colombel;Gut,2013
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献